Becton Dickinson

BD Ventures functions as the company's dedicated corporate venture capital group, typically investing from Series A through growth-stage rounds with check sizes between $5 million and $25 million. The group focuses on medical technology startups that align with BD's three business segments: medication management, diagnostics, and interventional products. Portfolio companies frequently gain access to BD's regulatory affairs team and global distribution network alongside the capital commitment.

BD is a publicly traded Fortune 500 medical technology corporation, not a family office or private investment partnership. Its investment activity is conducted on its own corporate balance sheet through BD Ventures and its corporate development team, with returns measured by strategic alignment and eventual commercial integration rather than standalone financial IRR. The governance structure subjects all material investments to the oversight of BD's board of directors and public-company disclosure requirements, which differs fundamentally from the private governance of a single-family office.

BD uses both tools as part of a continuum. Minority venture investments allow the company to monitor emerging technologies and build relationships with management teams before committing to full acquisitions. When a technology proves clinically validated and strategically central, BD typically moves to acquire the company outright — as it did with the $12.2 billion acquisition of CareFusion in 2015 and the $24 billion purchase of C.R. Bard in 2017. The corporate venture portfolio serves as both a strategic radar and an acquisition pipeline.

BD Ventures concentrates on areas where the parent company has existing commercial infrastructure and regulatory expertise, which means it generally avoids pure-play therapeutics, drug discovery, and biotechnology investments outside of companion diagnostics or delivery systems. The group also does not typically invest in healthcare services companies, health insurance technology, or direct-to-consumer health products that fall outside BD's medical-device and diagnostic core.

BD Ventures regularly co-invests alongside traditional life-sciences venture capital firms, including established healthcare specialists. This syndication approach allows BD to leverage external due diligence, share risk on earlier-stage assets, and access deal flow that originates outside the company's own network. The firm's ability to serve as a strategic co-investor often gives external VCs a path to eventual liquidity through BD's acquisition capability.

BD Ventures reports through the company's corporate strategy function, and all material investments require standard public-company governance approvals. The chief executive officer and board of directors maintain visibility into the venture portfolio, and investments exceeding certain materiality thresholds are disclosed in BD's SEC filings. This structure ensures that venture activity stays aligned with the long-term strategic priorities of the publicly traded parent company.

In April 2024, BD completed the separation of its Diabetes Care unit as Embecta, a standalone publicly traded company, marking one of the largest pure-play diabetes device spin-offs. The separation allows BD's corporate venture arm to intensify its focus on the higher-growth segments of smart connected devices, advanced diagnostics, and interventional products, freeing both management bandwidth and balance-sheet capacity for investments in those areas.